Most writing about AI in pharma fixes on the wrong question. It asks where the data has to live, as though a residency rule were the constraint. For a Basel life-sciences company there is no such rule: Switzerland has no localization mandate for pharma or research data. The binding question is different and harder. Can you prove the AI system is validated, that you can control and explain it, that its records are intact, and that a qualified human owns every regulated decision it touches? Answer that well and a great deal of document-heavy work becomes automatable. Answer it badly and the tool is unusable inside a GxP environment, however clever it is.
That distinction is what separates this guide from generic material, and from the broader Swiss picture. For the canonical treatment of the Federal Act on Data Protection, the Swiss labour economics, and the data-sovereignty argument, see the Switzerland finance and pharma cornerstone; for the banking and the wealth-and-commodities angles, the Zurich and Geneva guides. Basel's distinct subject is life sciences, and the regulated reality of putting AI to work in it.
The Basel density story
Few places concentrate this work like Basel. Roche is headquartered there, one of the largest research-and-development spenders in global pharmaceuticals; Novartis is headquartered there too; and Lonza, a world-leading contract development and manufacturing organisation, is a Basel company with on the order of 18,000 to 20,000 employees. Around those anchors sits the densest life-sciences cluster in Europe, a trinational region spanning Switzerland, France, and Germany that is reported to hold more than 800 life-sciences companies and over 33,000 specialists.
The point for automation is that the same document-heavy bottlenecks repeat across all of them: regulatory submissions, safety reports, clinical documentation, quality records. The biggest names build in-house, but the hundreds of mid-size pharma, biotech, and service firms next door run the identical regulated workflows by hand.
The real constraint, in three parts
The reason to keep this work private is not one thing, it is three, and they reinforce each other.
The first is intellectual property. In drug research the data is the trade secret. Molecular structures, target profiles, proprietary datasets, and trial designs are the asset, and exposing them to a hosted general-purpose model is a confidentiality risk with no upside. The second is GxP data integrity. Anything touching good-practice work has to preserve ALCOA+ integrity, the principle that records are attributable, legible, contemporaneous, original, accurate, and complete, consistent, enduring, and available, with the audit trails and electronic-signature controls that 21 CFR Part 11 and EU Annex 11 require. The third is validatability. An AI tool inside a computerised system has to be validated, and a hosted black box whose behaviour you cannot pin down or explain is hard to validate by design.
A private, on-premise build where data never leaves your environment answers all three in one move. The trade secret stays inside. The audit trail and the integrity controls are yours to operate. And because the system is full-code, its behaviour is deterministic, logged, access-controlled, and auditable, which is exactly what a validation exercise needs to bite on. The architecture and its rationale are set out in private AI on-premise; Basel is where the validation requirement makes the case unusually concrete.
The regulator picture, current and correct
The regulatory ground is moving quickly, and almost all of it points the same way: risk-based credibility, data governance, and a human kept firmly in the loop. The instruments that matter as of mid-2026 are worth setting out plainly, because several are still drafts and should be treated as such.
| Instrument | Body | Status, mid-2026 | Nature |
|---|---|---|---|
| Reflection paper on AI in the medicinal product lifecycle | EMA | Finalised (Sept 2024) | Non-binding |
| Draft guidance on AI to support regulatory decision-making | FDA | Draft (Jan 2025) | Non-binding |
| Guiding Principles of Good AI Practice in Drug Development | FDA and EMA | Published, early 2026 (reported) | Non-binding, ten principles |
| Annex 11 revision and new Annex 22 on AI | EU GMP | Draft (July 2025 consultation) | Draft; would be binding GMP only if and when finalised (timing unconfirmed) |
| Framework conditions for AI in medicinal product development | Swissmedic | Published | Non-binding framework guidance |
| GAMP 5 Second Edition and GAMP Guide: AI | ISPE | Published (2022, 2025) | Industry standard |
A few points carry the section. The EMA's reflection paper puts responsibility squarely on the applicant, holder, sponsor, and manufacturer, and for opaque models it expects interpretability and demonstrable human oversight. The FDA's draft introduces a risk-based, seven-step credibility assessment tied to a defined context of use. The first of the ten joint FDA and EMA principles, published in early 2026, is Human-Centric by Design. And the EU's July 2025 drafts are significant: Annex 11 expands several-fold, and the brand-new draft Annex 22 would be the first explicit GMP framework for AI, with the draft restricting critical GMP uses to static, deterministic models and keeping continuously-learning and generative models to non-critical applications under documented human oversight, with a qualified human evaluating the output.
Swissmedic ties this together for a Basel company. It has published framework conditions for AI that explicitly take account of the EMA, FDA, ICH, and WHO texts, and it places the documentation and justification burden on the applicant. Switzerland is not in the EU, and the mutual-recognition update with the EU has stalled, so a Basel firm often runs parallel Swiss and EU pathways rather than one. But Switzerland is a member of the international GMP inspection convention and aligns with EU GMP, so the Annex 11 and ALCOA+ expectations reach a Basel client regardless.
What must stay human
Against that backdrop, four decisions are not automatable, and a credible system is designed around them rather than over them.
- Batch certification and release is the personal, non-delegable responsibility of a Qualified Person under Annex 16, transferable only to another Qualified Person. AI can assemble and check the batch record; the QP certifies it.
- Pharmacovigilance causality and medical assessment require qualified human judgement and the QPPV. AI can take in the case and pre-screen signals; the safety physician decides.
- Regulatory submission sign-off stays with regulatory affairs. AI can assemble the dossier; a person owns what is filed.
- Clinical decisions stay with clinicians.
In every pairing the same shape holds: the system does the assembly, a qualified human makes the call and carries the accountability.
How you actually validate an AI tool
Because the system has to be validated, how you validate matters. The current framework is GAMP 5 Second Edition, which already accommodates AI and machine learning, now joined by a dedicated ISPE guide for AI in GxP systems, and by the FDA's signalled direction in its computer-software-assurance guidance, from exhaustive computer-system validation toward a risk-based approach that concentrates effort where patient safety and product quality are most at stake. Underneath all of it sit the Part 11 and Annex 11 controls and ALCOA+ integrity, which do not relax because an AI is involved; if anything the AI's training data, configuration, prompts, inferences, and human reviews all become things that must themselves be logged and attributable.
This is exactly where a full-code, private build earns its keep over a hosted service. Deterministic behaviour, complete logging, access control, and a clean audit trail are the raw material a validation exercise needs. We build that substrate; your quality and validation people qualify it for its intended use within your own quality system. The broader pattern for private AI in a regulated, auditable setting is set out in private AI for UK regulated businesses, and we are explicit about the limit: we do not make you compliant or validated, we build something you can validate.
What to automate first
Ranked by how mature and low-risk the use case is, this is the sensible order, and every item carries its human-control caveat:
- Pharmacovigilance case intake and MedDRA coding. The most mature use case, with industry-reported processing reductions that are large; the system codes and drafts, the safety physician confirms causality. This and the related data-reconciliation work draw on the same data-extraction techniques used elsewhere.
- Literature monitoring and systematic review screening. High-volume screening with reported time savings; a human owns inclusion decisions.
- Clinical study reports and medical writing. Drafting against the source data and templates, with the medical writer and reviewers owning the content.
- eCTD submission assembly and regulatory intelligence. Assembling and checking the dossier, which is structured document-processing work; regulatory affairs signs it off.
- GMP quality documentation. Drafting deviation reports, change controls, and CAPA records, with QA owning every disposition.
Efficiency figures circulate freely in this market and some are striking, but they are industry-reported and depend entirely on a firm's data and process, so we treat them as illustration rather than a result we commit to in advance.
The Swiss multiplier
There is a particular reason automation pays in Basel. Because Switzerland sits outside the EU and the mutual-recognition update has stalled, a Basel company frequently maintains parallel Swissmedic and EMA pathways, duplicate safety systems, and separate filing effort. Recruiter and industry surveys, which are indicative rather than official, describe acute scarcity in regulatory affairs and pharmacovigilance and a meaningful staffing premium tied to the non-EU position. Automation removes the duplicated document load without adding headcount in a market where that headcount is both scarce and among the most expensive anywhere. The way that return is calculated against senior salaries is set out in the true cost of your most expensive roles, and we make it in any currency.
Build, buy, or a private bespoke build
The honest market picture is build-and-buy, not either-or. The largest firms run in-house AI, and validated platforms from the established life-sciences software vendors cover a great deal. We do not compete with either, and we do not claim to outperform them. The recurring problem, and the reason only a small share of pharma has captured measurable value from AI, is that the data sits in silos and the integration is the hard part. That bespoke private integration layer, the connective work that joins an AI capability to your existing safety database, regulatory information system, and quality records while keeping everything inside your environment, is the gap we fill. The reasoning for an owned, full-code system over a generic one is in full-code AI automation.
Working with us
Ayoob AI is an engineering firm based in Newcastle upon Tyne with a second office in Dubai, delivering to Swiss clients remotely. We build private, on-premise systems where research, clinical, and quality data never leaves your environment, we are ISO 27001:2022 and Cyber Essentials certified, and we hold five pending UK patents on the on-device compute that makes that private model practical. We are not a contract research organisation, not a regulatory or GxP consultancy, and not a manufacturer, so validation and every clinical, medical, safety, regulatory, and batch-release decision, with the responsibility for them, stay with you and your quality and regulatory functions. Our retainers run from GBP 4,000 to GBP 6,000 per month as of June 2026, argued against the cost of the scarce people whose routine load we remove.
If you run a pharma, biotech, or life-sciences operation in the Basel region and want to know which parts of your regulated document load can be automated inside a validatable, private system, that is the conversation we have on a discovery call, which you can start through our AI automation service.
Related reading
- AI Automation for Switzerland's Finance and Pharma Sector
- AI Automation for Zurich Banking and Insurance
- AI Automation for Geneva Private Banking and Commodity Trading
- Private AI On-Premise
- Private AI for UK Regulated Businesses: A 2026 Decision Framework
- AI Document Processing
- The True Cost of Your Most Expensive Roles, and What Automating Them Returns
